Stock Track | OPKO Health Plunges 6.25% Pre-market on Weak Q3 Outlook and Q2 Results

Stock Track
08-01

OPKO Health (OPK) shares tumbled 6.25% in pre-market trading on Friday, following the release of its Q2 2025 financial results and a disappointing outlook for the third quarter. The biopharmaceutical and diagnostics company is facing headwinds as analysts project a loss and declining revenue for the upcoming quarter.

According to the latest earnings preview, OPKO Health is expected to report a loss of 7 cents per share for the quarter ending September 30, 2025. Analysts estimate a 3.7% decrease in revenue to $167.222 million, down from $173.6 million in the same period last year. This projection reflects ongoing challenges in the company's business segments and may have spooked investors.

Adding to the pessimistic sentiment, the mean earnings estimate for OPKO Health has fallen by about 4.4% over the past three months, indicating a deteriorating outlook among analysts. Despite these challenges, it's worth noting that the current average analyst rating on OPKO shares remains a "strong buy," with a median 12-month price target of $3.00, significantly above its last closing price. However, the market seems to be focusing on the near-term headwinds, as evidenced by today's pre-market decline.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10